Hedvika Lazar
Geschäftsführer bei Vaderis Therapeutics AG
Profil
Hedvika Lazar is currently the Director of Clinical Science & Operations at Vaderis Therapeutics AG.
Prior to this, she worked as the Manager of Clinical Development at Kenta Biotech AG from 2006.
She has also worked as a Principal at Berna Biotech AG and MDS Pharma Services (Canada).
Aktive Positionen von Hedvika Lazar
Unternehmen | Position | Beginn |
---|---|---|
Kenta Biotech AG
Kenta Biotech AG BiotechnologyHealth Technology Kenta Biotech AG engages in the research, development, production, and marketing of biotechnological and pharmaceutical products. It also specializes in the discovery and development of monoclonal antibodies for the treatment of life-threatening hospital infections. The company was founded by Alois B. Lang on February 9, 2006 and is headquartered in Zug, Switzerland. | Corporate Officer/Principal | 01.01.2006 |
Vaderis Therapeutics AG
Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | Geschäftsführer | - |
Ehemalige bekannte Positionen von Hedvika Lazar
Unternehmen | Position | Ende |
---|---|---|
MDS Pharma Services (Canada)
MDS Pharma Services (Canada) Miscellaneous Commercial ServicesCommercial Services MDS Pharma Services provides contract drug discovery and drug development services for pharmaceutical and biotechnology companies. It provides its clients with early-stage, clinical research and late-stage drug discovery and development services, such as Phase I-IV testing, target discovery and lead optimization. The company is located in Saint-Laurent, Canada. | Corporate Officer/Principal | - |
Berna Biotech AG
Berna Biotech AG Miscellaneous Commercial ServicesCommercial Services Berna Biotech AG produced and developed immunobiological preparations. It offered respiratory, hepatitis B, pediatric, veterinary and travel vaccines. The company was founded in 1898 and was headquartered in Bern, Switzerland | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Berna Biotech AG
Berna Biotech AG Miscellaneous Commercial ServicesCommercial Services Berna Biotech AG produced and developed immunobiological preparations. It offered respiratory, hepatitis B, pediatric, veterinary and travel vaccines. The company was founded in 1898 and was headquartered in Bern, Switzerland | Commercial Services |
MDS Pharma Services (Canada)
MDS Pharma Services (Canada) Miscellaneous Commercial ServicesCommercial Services MDS Pharma Services provides contract drug discovery and drug development services for pharmaceutical and biotechnology companies. It provides its clients with early-stage, clinical research and late-stage drug discovery and development services, such as Phase I-IV testing, target discovery and lead optimization. The company is located in Saint-Laurent, Canada. | Commercial Services |
Vaderis Therapeutics AG
Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | Health Technology |
Kenta Biotech AG
Kenta Biotech AG BiotechnologyHealth Technology Kenta Biotech AG engages in the research, development, production, and marketing of biotechnological and pharmaceutical products. It also specializes in the discovery and development of monoclonal antibodies for the treatment of life-threatening hospital infections. The company was founded by Alois B. Lang on February 9, 2006 and is headquartered in Zug, Switzerland. | Health Technology |